Financing momentum CDT recently secured $10M in seed financing in December 2024, signaling growth momentum and potential for increased R&D spend among clients seeking early-stage drug discovery partnerships.

Early-stage focus As a full-service CRO specializing in early-stage drug discovery and development, CDT offers end-to-end support from concept to IND filing, presenting opportunities to engage clients at the outset of their programs.

Strategic location Operations in Saint Louis, Missouri place CDT in a central U.S. hub for life sciences collaborations, enabling regional outreach to biotech startups and academic partnerships seeking cost-effective, high-quality analytics and discovery services.

Integrated capabilities CDT delivers a broad suite across biochemistry, cell biology, mechanistic enzymology, in vivo pharmacology, and translational biology, which can be positioned to replace or augment multiple incumbent CROs for end-to-end pipelines.

Past acquisitions and banking ties Historical financing and corporate actions, including prior acquisition by Aclaris and a bank financing arrangement with SVB, suggest a track record of collaboration with pharma players and potential credibility when approaching pharma and biotech customers negotiating terms.